Close Menu
August 28, 2019
Sponsored by
Horizon Discovery

Beyond Cas9: CRISPR Gene Editing with Alternative Nucleases

GenomeWebinar

Director of the Center for Advance Genome Engineering,
St. Jude Children’s Research Hospital

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Genome editing using the CRISPR-Cas9 platform enables precise genetic manipulations within complex genomes. Although wild-type Streptococcus pyogenes Cas9 (SpCas9) was the first detailed CRISPR platform, this widely used nuclease is still limited by the canonical 5’-NGG-3’ protospacer adjacent motif required for SpCas9 binding and cleavage.

In this webinar, Shondra Miller of St. Jude Children's Research Hospital will discuss the pros and cons of several Cas9 variants and orthologues and how these alternative nucleases can be applied to genome editing workflows.

Sponsored by

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.